{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T17:51:00Z","timestamp":1791827460145,"version":"4.3.4"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:00:00Z","timestamp":1791763200000},"content-version":"vor","delay-in-days":82,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-026-08690-1","type":"journal-article","created":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T13:46:02Z","timestamp":1784727962000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The role of IFNLR1 in modulating T cell infiltration and cancer progression in renal cell carcinoma"],"prefix":"10.1186","volume":"24","author":[{"given":"Yawen","family":"Zheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yufeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingyan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengmeng","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinchao","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feifei","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meili","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,22]]},"reference":[{"issue":"10451","key":"8690_CR1","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/S0140-6736(24)00917-6","volume":"404","author":"M Young","year":"2024","unstructured":"Young M, Jackson-Spence F, Beltran L, Day E, Suarez C, Bex A, et al. Renal cell carcinoma. Lancet. 2024;404(10451):476\u201391. https:\/\/doi.org\/10.1016\/S0140-6736(24)00917-6.","journal-title":"Lancet"},{"issue":"4","key":"8690_CR2","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1038\/s43018-025-00942-1","volume":"6","author":"MB Mckinnon","year":"2025","unstructured":"Mckinnon MB, Rini BI, Haake S M. Biomarker-informed care for patients with renal cell carcinoma. Nat Cancer. 2025;6(4):573\u201383. https:\/\/doi.org\/10.1038\/s43018-025-00942-1.","journal-title":"Nat Cancer"},{"issue":"3","key":"8690_CR3","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1159\/000345365","volume":"5","author":"Y Zheng","year":"2013","unstructured":"Zheng Y, Li H, Yu J, Zhao H, Wang SE, Ren X-B. Interferon-\u03bbs: special immunomodulatory agents and potential therapeutic targets. J Innate Immun. 2013;5(3):209\u201318. https:\/\/doi.org\/10.1159\/000345365.","journal-title":"J Innate Immun"},{"key":"8690_CR4","doi-asserted-by":"publisher","unstructured":"Wang B, Zhou B, Chen J, Sun X, Yang W, Yang T, et al. Type III interferon inhibits bladder cancer progression by reprogramming macrophage-mediated phagocytosis and orchestrating effective immune responses. J Immunother Cancer. 2024;12(4):e 7808. https:\/\/doi.org\/10.1136\/jitc-2023-007808.","DOI":"10.1136\/jitc-2023-007808"},{"issue":"3","key":"8690_CR5","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s12032-023-02276-3","volume":"41","author":"JL Ha","year":"2024","unstructured":"Ha JL, Kaser E, Guan T, Mayberry TG, Smith LA, D\u2019mello K, et al. Up and away with cervical cancer: IL-29 is a promising cytokine for immunotherapy of cervical cancer due to its powerful upregulation of p18, p27, and TRAILR1. Med Oncol. 2024;41(3):65. https:\/\/doi.org\/10.1007\/s12032-023-02276-3.","journal-title":"Med Oncol"},{"issue":"1","key":"8690_CR6","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1186\/s12967-023-04453-4","volume":"21","author":"ZZ Wang","year":"2023","unstructured":"Wang ZZ, Wen XL, Wang N, Li XH, Guo Y, Zhu X, et al. Portraying the dark side of endogenous IFN-\u03bb for promoting cancer progression and immunoevasion in pan-cancer. J Transl Med. 2023;21(1):615. https:\/\/doi.org\/10.1186\/s12967-023-04453-4.","journal-title":"J Transl Med"},{"issue":"10","key":"8690_CR7","doi-asserted-by":"publisher","first-page":"101558","DOI":"10.1016\/j.jcmgh.2025.101558","volume":"19","author":"R Yu","year":"2025","unstructured":"Yu R, Zhang C, Yuan M, Ye S, Hu T, Chen S, et al. Exercise-induced metabolite N-lactoyl-phenylalanine ameliorates colitis by inhibiting M1 macrophage polarization via the suppression of the NF-\u03baB signaling Pathway. Cellular Mol Gastroenterol Hepatol. 2025;19(10):101558. https:\/\/doi.org\/10.1016\/j.jcmgh.2025.101558.","journal-title":"Cellular Mol Gastroenterol Hepatol"},{"key":"8690_CR8","doi-asserted-by":"publisher","first-page":"217007","DOI":"10.1016\/j.canlet.2024.217007","volume":"597","author":"M Yuan","year":"2024","unstructured":"Yuan M, Zhang C, Chen S, Ye S, Liu H, Ke H, et al. PDP1 promotes KRAS mutant colorectal cancer progression by serving as a scaffold for BRAF and MEK1. Cancer Lett. 2024;597:217007. https:\/\/doi.org\/10.1016\/j.canlet.2024.217007.","journal-title":"Cancer Lett"},{"issue":"12","key":"8690_CR9","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.1038\/s41418-025-01533-4","volume":"32","author":"C Zhang","year":"2025","unstructured":"Zhang C, Yu R, Li S, Yuan M, Hu T, Liu J, et al. KRAS mutation increases histone H3 lysine 9 lactylation (H3K9la) to promote colorectal cancer progression by facilitating cholesterol transporter GRAMD1A expression. Cell Death Differ. 2025;32(12):2225\u201338. https:\/\/doi.org\/10.1038\/s41418-025-01533-4.","journal-title":"Cell Death Differ"},{"key":"8690_CR10","doi-asserted-by":"publisher","first-page":"114579","DOI":"10.1016\/j.intimp.2025.114579","volume":"155","author":"J Liu","year":"2025","unstructured":"Liu J, Su Y, Zhang C, Dong H, Yu R, Yang X, et al. NCOA3 impairs the efficacy of anti-PD-L1 therapy via HSP90\u03b1\/EZH2\/CXCL9 axis in colon cancer. Int Immunopharmacol. 2025;155:114579. https:\/\/doi.org\/10.1016\/j.intimp.2025.114579.","journal-title":"Int Immunopharmacol"},{"key":"8690_CR11","doi-asserted-by":"publisher","first-page":"102424","DOI":"10.1016\/j.coi.2024.102424","volume":"87","author":"H Gewaid","year":"2024","unstructured":"Gewaid H, Bowie A G. Regulation of type I and type III interferon induction in response to pathogen sensing. Curr Opin Immunol. 2024;87:102424. https:\/\/doi.org\/10.1016\/j.coi.2024.102424.","journal-title":"Curr Opin Immunol"},{"issue":"1","key":"8690_CR12","doi-asserted-by":"publisher","first-page":"3045","DOI":"10.1038\/s41467-025-58220-8","volume":"16","author":"C Sakref","year":"2025","unstructured":"Sakref C, Saby A, Rodriguez C, Ardin M, Moudombi L, Doffin A-C, et al. Type III interferon primes pDcs for TLR7 activation and antagonizes immune suppression mediated by TGF-\u03b2 and PGE2. Nat Commun. 2025;16(1):3045. https:\/\/doi.org\/10.1038\/s41467-025-58220-8.","journal-title":"Nat Commun"},{"issue":"3","key":"8690_CR13","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.immuni.2019.07.007","volume":"51","author":"A Forero","year":"2019","unstructured":"Forero A, Ozarkar S, Li H, Lee CH, Hemann EA, Nadjsombati MS, et al. Differential activation of the transcription factor IRF1 underlies the distinct immune responses elicited by type I and type III interferons. Immunity. 2019;51(3):451\u201364.e6. https:\/\/doi.org\/10.1016\/j.immuni.2019.07.007.","journal-title":"Immunity"},{"key":"8690_CR14","doi-asserted-by":"publisher","first-page":"102413","DOI":"10.1016\/j.coi.2024.102413","volume":"86","author":"NA de Weerd","year":"2024","unstructured":"de Weerd NA, Kurowska A K, Mendoza J L, Schreiber G. Structure\u2013function of type I and III interferons. Curr Opin Immunol. 2024;86:102413. https:\/\/doi.org\/10.1016\/j.coi.2024.102413.","journal-title":"Curr Opin Immunol"},{"key":"8690_CR15","doi-asserted-by":"publisher","first-page":"102430","DOI":"10.1016\/j.coi.2024.102430","volume":"87","author":"A Piperakis","year":"2024","unstructured":"Piperakis A, Galani I E, Andreakos E. Type III interferons in innate and adaptive immunity in the respiratory tract. Curr Opin Immunol. 2024;87:102430. https:\/\/doi.org\/10.1016\/j.coi.2024.102430.","journal-title":"Curr Opin Immunol"},{"key":"8690_CR16","doi-asserted-by":"publisher","first-page":"102412","DOI":"10.1016\/j.coi.2024.102412","volume":"86","author":"AP Wright","year":"2024","unstructured":"Wright AP, Nice T J. Role of type-I and type-III interferons in gastrointestinal homeostasis and pathogenesis. Curr Opin Immunol. 2024;86:102412. https:\/\/doi.org\/10.1016\/j.coi.2024.102412.","journal-title":"Curr Opin Immunol"},{"key":"8690_CR17","doi-asserted-by":"publisher","first-page":"102400","DOI":"10.1016\/j.coi.2023.102400","volume":"86","author":"ML Stanifer","year":"2024","unstructured":"Stanifer ML, Boulant S. Differential signaling by type-I and type-III interferons in mucosa. Curr Opin Immunol. 2024;86:102400. https:\/\/doi.org\/10.1016\/j.coi.2023.102400.","journal-title":"Curr Opin Immunol"},{"issue":"2","key":"8690_CR18","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1111\/imm.13954","volume":"176","author":"B Tang","year":"2025","unstructured":"Tang B, Liu Z, Xiong H, Zhang J, Dai J. IFN -\u03bb: unleashing its potential in disease therapies from acute inflammation regulation to cancer immunotherapy. Immunology. 2025;176(2):197\u2013214. https:\/\/doi.org\/10.1111\/imm.13954.","journal-title":"Immunology"},{"issue":"1","key":"8690_CR19","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1089\/jir.2018.0046","volume":"39","author":"A Lasfar","year":"2019","unstructured":"Lasfar A, Zloza A, Silk A W, Lee LY, Cohen-Solal KA. Interferon lambda: toward a dual role in Cancer. J Interferon Cytokine Res. 2019;39(1):22\u201329. https:\/\/doi.org\/10.1089\/jir.2018.0046.","journal-title":"J Interferon Cytokine Res"},{"issue":"6","key":"8690_CR20","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.3390\/life13061310","volume":"13","author":"SA Weir","year":"2023","unstructured":"Weir SA, Kc K, Shoaib S, Yusuf N. The Immunotherapeutic role of type I and III interferons in melanoma and non-melanoma skin Cancers. Life (Basel, Switzerland), Life. 2023;13(6):1310. https:\/\/doi.org\/10.3390\/life13061310.","journal-title":"Life"},{"issue":"2","key":"8690_CR21","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1158\/1535-7163.MCT-09-0461","volume":"9","author":"KD Guenterberg","year":"2010","unstructured":"Guenterberg KD, Grignol VP, Raig ET, Zimmerer JM, Chan AN, Blaskovits FM, et al. Interleukin-29 binds to melanoma cells inducing jak-STAT signal transduction and apoptosis. Mol Cancer Ther. 2010;9(2):510\u201320. https:\/\/doi.org\/10.1158\/1535-7163.MCT-09-0461.","journal-title":"Mol Cancer Ther"},{"issue":"2","key":"8690_CR22","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.trecan.2024.11.011","volume":"11","author":"K Ma","year":"2025","unstructured":"Ma K, Wang L, Li W, Tang T, Ma B, Zhang L, et al. Turning cold into hot: emerging strategies to fire up the tumor microenvironment. Trends Cancer. 2025;11(2):117\u201334. https:\/\/doi.org\/10.1016\/j.trecan.2024.11.011.","journal-title":"Trends Cancer"},{"issue":"1","key":"8690_CR23","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1038\/s41392-025-02266-z","volume":"10","author":"J Song","year":"2025","unstructured":"Song J, Yang P, Chen C, Ding W, Tillement O, Bai H, et al. Targeting epigenetic regulators as a promising avenue to overcome cancer therapy resistance. Signal transduction and targeted therapy, 2025. Signal Transduct Targeted Ther. 10(1):219. https:\/\/doi.org\/10.1038\/s41392-025-02266-z.","journal-title":"Signal Transduct Targeted Ther"},{"issue":"5","key":"8690_CR24","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1053\/j.gastro.2019.07.031","volume":"157","author":"C G\u00fcnther","year":"2019","unstructured":"G\u00fcnther C, Ruder B, Stolzer I, Dorner H, He G-W, Chiriac MT, et al. Interferon lambda promotes paneth cell death via STAT1 signaling in mice and is increased in inflamed ileal tissues of patients with Crohn\u2019s Disease. Gastroenterology. 2019;157(5):1310\u201322.e13. https:\/\/doi.org\/10.1053\/j.gastro.2019.07.031.","journal-title":"Gastroenterology"},{"key":"8690_CR25","doi-asserted-by":"publisher","unstructured":"Lin P, Lin Y, Chen X, Zhao X, Cui L. Decoding MHC loss: molecular mechanisms and implications for immune resistance in cancer. Clin Transl Med. 2025;15(7):e70403. https:\/\/doi.org\/10.1002\/ctm2.70403.","DOI":"10.1002\/ctm2.70403"},{"issue":"5","key":"8690_CR26","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.4049\/jimmunol.2000225","volume":"205","author":"M Benhammadi","year":"2020","unstructured":"Benhammadi M, Math\u00e9 J, Dumont-Lagac\u00e9 M, Kobayashi KS, Gaboury L, Brochu S, et al. IFN-\u03bb enhances constitutive expression of MHC Class I molecules on thymic epithelial Cells. J Immunol Md (2020). 2020;205(5):1268\u201380. https:\/\/doi.org\/10.4049\/jimmunol.2000225.","journal-title":"J Immunol"},{"key":"8690_CR27","doi-asserted-by":"crossref","unstructured":"Goel RR, Wang X, O\u2019Neil LJ, et al. Interferon lambda promotes immune dysregulation and tissue inflammation in TLR7-induced lupus. Proceedings of the National Academy of Sciences of the United States of America. 2020;117(10):5409\u201319.","DOI":"10.1073\/pnas.1916897117"},{"issue":"3","key":"8690_CR28","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1159\/000345365","volume":"5","author":"YW Zheng","year":"2013","unstructured":"Zheng YW, Li H, Yu J P, Zhao H, Wang SE, Ren X-B. Interferon-\u03bbs: special immunomodulatory agents and potential therapeutic targets. J Innate Immun. 2013;5(3):209\u201318. https:\/\/doi.org\/10.1159\/000345365.","journal-title":"J Innate Immun"},{"issue":"3","key":"8690_CR29","doi-asserted-by":"publisher","first-page":"152389","DOI":"10.1016\/j.imbio.2023.152389","volume":"228","author":"TV Larsen","year":"2023","unstructured":"Larsen TV, Daugaard TF, Gad HH, Hartmann R, Nielsen AL. PD-L1 and PD-L2 immune checkpoint protein induction by type III interferon in non-small cell lung cancer cells. Immunobiology. 2023;228(3):152389. https:\/\/doi.org\/10.1016\/j.imbio.2023.152389.","journal-title":"Immunobiology"},{"key":"8690_CR30","doi-asserted-by":"publisher","first-page":"782852","DOI":"10.3389\/fimmu.2021.782852","volume":"12","author":"F Vitiello G A","year":"2021","unstructured":"Vitiello G A F, Ferreira W A S, Cordeiro De Lima V C, Medina TDS. Antiviral responses in cancer: boosting antitumor immunity through activation of interferon pathway in the tumor Microenvironment. Front Immunol. 2021;12:782852. https:\/\/doi.org\/10.3389\/fimmu.2021.782852.","journal-title":"Front Immunol"},{"issue":"8","key":"8690_CR31","doi-asserted-by":"publisher","first-page":"4468","DOI":"10.1158\/0008-5472.CAN-05-3653","volume":"66","author":"A Lasfar","year":"2006","unstructured":"Lasfar A, Lewis-Antes A, Smirnov S V, Anantha S, Abushahba W, Tian B, et al. Characterization of the Mouse IFN-\u03bb ligand-receptor system: IFN-\u03bbs exhibit antitumor activity against B16 melanoma. Cancer Res. 2006;66(8):4468\u201377. https:\/\/doi.org\/10.1158\/0008-5472.CAN-05-3653.","journal-title":"Cancer Res"},{"issue":"22","key":"8690_CR32","doi-asserted-by":"publisher","first-page":"5047","DOI":"10.1158\/1078-0432.CCR-15-0685","volume":"21","author":"L Mart\u00ednez-Lostao","year":"2015","unstructured":"Mart\u00ednez-Lostao L, Anel A, Pardo J. How do cytotoxic lymphocytes kill cancer cells? J Am Assoc Cancer Res. 2015;21(22):5047\u201356. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-0685.","journal-title":"Clin Cancer Res: Off J Am Assoc Cancer Res"},{"key":"8690_CR33","doi-asserted-by":"publisher","unstructured":"G\u00f3mez-Mor\u00f3n \u00c1, Gonz\u00e1lez-Pinar A, Carrasco-Padilla C, Roda-Navarro P, Mart\u00edn-C\u00f3freces NB. Exploring how cytoskeleton dynamics tunes T cell activation at the immunological Synapse. Eur J Immunol. 2025;55(8):e70028. https:\/\/doi.org\/10.1002\/eji.70028.","DOI":"10.1002\/eji.70028"},{"issue":"9","key":"8690_CR34","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1038\/ni.3795","volume":"18","author":"K Araki","year":"2017","unstructured":"Araki K, Morita M, Bederman A G, Konieczny BT, Kissick HT, Sonenberg N, et al. Translation is actively regulated during the differentiation of CD8+ effector T cells. Nat Immunol. 2017;18(9):1046\u201357. https:\/\/doi.org\/10.1038\/ni.3795.","journal-title":"Nat Immunol"},{"issue":"6","key":"8690_CR35","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.4049\/jimmunol.2100537","volume":"209","author":"D Salloum","year":"2022","unstructured":"Salloum D, Singh K, Davidson N R, Cao L, Kuo D, Sanghvi VR, et al. A rapid translational immune response program in CD8 memory T Lymphocytes. J Immunol, Md, 1950), 2022;209(6):1189\u201399. https:\/\/doi.org\/10.4049\/jimmunol.2100537.","journal-title":"J Immunol"},{"issue":"9","key":"8690_CR36","doi-asserted-by":"publisher","first-page":"2662","DOI":"10.3390\/cancers12092662","volume":"12","author":"MD Tucker","year":"2020","unstructured":"Tucker MD, Rini B I. Predicting response to immunotherapy in metastatic renal cell Carcinoma. Cancers. 2020;12(9):2662. https:\/\/doi.org\/10.3390\/cancers12092662.","journal-title":"Cancers"},{"key":"8690_CR37","doi-asserted-by":"publisher","unstructured":"Cottrell TR, Lotze MT, Ali A, Bifulco CB, Capitini CM, Chow LQM, et al. Society for Immunotherapy of Cancer (SITC) consensus statement on essential biomarkers for immunotherapy clinical protocols. J Immunother Cancer. 2025;13(3):e10928. https:\/\/doi.org\/10.1136\/jitc-2024-010928.","DOI":"10.1136\/jitc-2024-010928"},{"issue":"1","key":"8690_CR38","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1038\/s41392-024-01979-x","volume":"9","author":"B Wu","year":"2024","unstructured":"Wu B, Zhang B, Li B, Wu H, Jiang M. Cold and hot tumors: from molecular mechanisms to targeted therapy. Signal transduction and targeted therapy, 2024. Signal Transduct Targeted Ther. 2024;9(1):274. https:\/\/doi.org\/10.1038\/s41392-024-01979-x.","journal-title":"Signal Transduct Targeted Ther"},{"issue":"1","key":"8690_CR39","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1038\/s41698-025-01003-7","volume":"9","author":"E Marei H","year":"2025","unstructured":"Marei H E. Epigenetic regulators in cancer therapy and progression. Npj Precis Onc. 2025;9(1):206. https:\/\/doi.org\/10.1038\/s41698-025-01003-7.","journal-title":"Npj Precis Onc"},{"key":"8690_CR40","doi-asserted-by":"publisher","unstructured":"Arthur SE, Sorgeloos F, Hosmillo M, Goodfellow IG. Epigenetic suppression of interferon lambda receptor expression leads to enhanced human norovirus replication in Vitro. mBio. 2019;10(5):e2119\u2013e 2155. https:\/\/doi.org\/10.1128\/mBio.02155-19.","DOI":"10.1128\/mBio.02155-19"},{"key":"8690_CR41","doi-asserted-by":"publisher","unstructured":"Ding S, Khoury-Hanold W, Iwasaki A, Robek MD. Epigenetic reprogramming of the type III interferon response potentiates antiviral activity and suppresses tumor Growth. PLoS Biol. 2014;12(1):e1001758. https:\/\/doi.org\/10.1371\/journal.pbio.1001758.","DOI":"10.1371\/journal.pbio.1001758"},{"key":"8690_CR42","doi-asserted-by":"publisher","first-page":"1512353","DOI":"10.3389\/fimmu.2024.1512353","volume":"15","author":"Y Sun","year":"2025","unstructured":"Sun Y, Liu Y, Jiang L, Zhong C. m5C methylation modification may be an accomplice in colorectal cancer escaping from anti-tumor effects of innate immunity-type I\/III interferon. Front Immunol. 2025;15:1512353. https:\/\/doi.org\/10.3389\/fimmu.2024.1512353.","journal-title":"Front Immunol"},{"key":"8690_CR43","doi-asserted-by":"publisher","first-page":"107271","DOI":"10.1016\/j.phrs.2024.107271","volume":"206","author":"Z Yang","year":"2024","unstructured":"Yang Z, Chu B, Tu Y, Li L, Chen D, Huang S, et al. Dual inhibitors of DNMT and HDAC remodels the immune microenvironment of colorectal cancer and enhances the efficacy of anti-PD-L1 therapy. Pharmacological Res. 2024;206:107271. https:\/\/doi.org\/10.1016\/j.phrs.2024.107271.","journal-title":"Pharmacological Res"},{"issue":"5","key":"8690_CR44","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.coi.2011.07.007","volume":"23","author":"V Kotenko S","year":"2011","unstructured":"Kotenko S V. IFN-\u03bbs. Current opinion in immunology, 2011. Curr Opin Immunol. 2011;23(5):583\u201390. https:\/\/doi.org\/10.1016\/j.coi.2011.07.007.","journal-title":"Curr Opin Immunol"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-026-08690-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08690-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08690-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T17:26:58Z","timestamp":1791826018000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12967-026-08690-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,22]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8690"],"URL":"https:\/\/doi.org\/10.1186\/s12967-026-08690-1","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,22]]},"assertion":[{"value":"8 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1285"}}